Mylan Q3 better than feared, recent selloff overdone, says JPMorgan
JPMorgan analyst Chris Schott views Mylan's Q3 results as "better than feared" and a "step in the right direction." While the company's North American business remains under pressure, year-over-year erosion for the business improved from Q2, overall gross margins showed solid year-over-year improvement and Mylan maintained its annual guidance, Schott tells investors in a post-earnings research note. The analyst views the recent weakness in the shares as overdone and keeps an Overweight rating on the name with a $45 price target. Looking beyond near-term challenges, Mylan is one of the better-positioned players in the space with a number of longer-term growth drivers in place, including biosimilars and the pending generic Advair approval, says Schott.